Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00328 ...
Drug Name Indomethacin
Molecular Weight 357.788
Molecular Formula C19H16ClNO4
CAS Number 53-86-1
SMILES COC1=CC2=C(C=C1)N(C(=O)C1=CC=C(Cl)C=C1)C(C)=C2CC(O)=O
External Links
DRUGBANK DB00328
T3DB T3D2753
PubChem Compound 3715
PDR 1360
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Caco-2 Permeability -4.69 - -4.69 - ADME Research, USCD
Log P 4.27 - 4.27 - HANSCH,C ET AL. (1995)
Melting Point 151.0 ℃ 151 ℃ U.S. Patent 3,161,654.
Water Solubility 0.937 mg/L 0.937 mg/L YALKOWSKY,SH & DANNENFELSER,RM 1992)
pKa 4.5 - 4.5 - BUDAVARI,S ET AL. (1989)
Log S -4.62 - -4.62 - ADME Research, USCD

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Bioavailability 100.0 % 100.0 % PO, oral; DRUGBANK
Bioavailability 85.0 % 80-90 % Rectal Administration; DRUGBANK
Bioavailability 100.0 % ~100 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 1540.0 ng/ml 1.54±0.76 ug/ml DRUGBANK
C Max 2650.0 ng/ml 2.65±1.03 ug/ml DRUGBANK
C Max 4920.0 ng/ml 4.92±1.88 ug/ml DRUGBANK
C Max 2400.0 ng/ml ~2.4 mcg/ml Oral single dose; food; The Pharmacological Basis of Therapeutics
T Max 1.4 h 0.9±0.4-1.5±0.8 h PO, oral; fasting; DRUGBANK
T Max 1.3 h ~1.3 h Oral single dose; food; The Pharmacological Basis of Therapeutics
Clearance 0.11 L/h/kg 1-2.5 ml/kg/min Plasma clearance; PO, oral; DRUGBANK
Clearance 0.0840 L/h/kg 1.4±0.2 ml/min/kg Neonates ↓ ;Elderly ↓ ;Prem, premature ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.0780 L/h/kg 1.3 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 0.96 L/kg 0.34-1.57 L/kg PO, oral; intravenous injection, IV; Rectal Administration; normal,healthy; DRUGBANK
Volume of Distribution 0.29 L/kg 0.29±0.04 L/kg Elderly → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.0960 L/kg 0.096 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 1.0 h 1 h distribution half-life; DRUGBANK
Half-life 6.9 h 2.6-11.2 h elimination half-life; DRUGBANK
Half-life 4.5 h ~4.5 h PO, oral; DRUGBANK
Half-life 20.0 h ~20 h elimination half-life; intravenous injection, IV; Neonates; DRUGBANK
Half-life 15.0 h 15 h Infants; weighing more than 1000g; DRUGBANK
Half-life 21.0 h 21 h Infants; weighing less than 1000g; DRUGBANK
Half-life 2.4 h 2.4±0.2 h Neonates ↑ ;Prem, premature ↑ ;rheumatoid arthritis → ;RD, renal impairment, Renal disease，including uremia → ;Age ↑ ; The Pharmacological Basis of Therapeutics
Half-life 1.4 h 1.4 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 2.4 mg/kg 2.42 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 13.0 mg/kg 13.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 50.0 mg/kg 50.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 12.0 mg/kg 12.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Toxicity LD50 50.0 mg/kg 50.0 mg/kg PO, oral; mouse; T3DB
Toxicity LD50 12.0 mg/kg 12.0 mg/kg PO, oral; Rattus, Rat; T3DB
Eliminate Route 60.0 % ~60 % Urinary excretion; PO, oral; DRUGBANK
Eliminate Route 33.0 % 33 % Faeces excretion; PO, oral; DRUGBANK
Eliminate Route 15.0 % 15±8 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 94.5 % 90-99 % plasma proteins; DRUGBANK
Protein Binding 90.0 % 90 % Neonates → ;hypoalbuminemia Alb → ;AIDS,HIV → ; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for neonates 0.25 mg/kg 0.25 mg/kg intravenous injection, IV Indocin Oral Suspension indomethacin PDR
Max dose for neonates 0.2 mg/kg 0.2 mg/kg intravenous injection, IV Indocin Oral Suspension indomethacin PDR
Max dose for children 4.0 mg/kg/day 4 mg/kg/day Capsule, PO, Oral;Liquid; Indocin Oral Suspension indomethacin PDR
Max dose for children 0.0 0 Indocin Oral Suspension indomethacin PDR
Max dose for children 175.0 mg/day 175 mg/day Capsule, PO, Oral;Liquid; Indocin Oral Suspension indomethacin PDR
Max dose for adolescents 100.0 mg/day 100 mg/day PO, oral Indocin Oral Suspension indomethacin PDR
Max dose for adolescents 4.0 mg/kg/day 4 mg/kg/day Capsule, PO, Oral;Liquid; Indocin Oral Suspension indomethacin PDR
Max dose for adolescents 175.0 mg/day 175 mg/day Capsule, PO, Oral;Liquid; Indocin Oral Suspension indomethacin PDR
Max dose for adults 200.0 mg/day 200 mg/day Capsule, PO, Oral;Liquid; Indocin Oral Suspension indomethacin PDR
Max dose for adults 120.0 mg 120 mg Capsule, PO, Oral Indocin Oral Suspension indomethacin PDR
Max dose for adults 150.0 mg/day 150 mg/day Capsule, PO, Oral Indocin Oral Suspension indomethacin PDR
Max dose for geriatric 200.0 mg/day 200 mg/day Capsule, PO, Oral;Liquid; Indocin Oral Suspension indomethacin PDR
Max dose for geriatric 120.0 mg 120 mg Capsule, PO, Oral Indocin Oral Suspension indomethacin PDR
Max dose for geriatric 150.0 mg/day 150 mg/day Capsule, PO, Oral Indocin Oral Suspension indomethacin PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1